18F-胆碱PET/CT的10年临床经验:意大利多中心对3343例患者的回顾性评估
这项意大利9个核医学科的多中心回顾性队列研究纳入2008年10月至2019年9月间3343例接受18F-胆碱PET/CT的前列腺癌患者,其中545例(16.4%)用于分期、2798例(83.6%)用于再分期,阳性率分别为99.1%和71.2%。阳性结果与高Gleason评分(>7)和高PSA水平相关(P<0.01)。分期时区分局部病变、淋巴结受累和转移的最佳PSA cutoff分别为9.2、16.4和16.6 ng/mL,再分期时为1.27 ng/mL。
要点
- 18F-胆碱PET/CT在再分期中阳性率为71.2%,在分期中为99.1%。
- 阳性结果与Gleason评分>7及高PSA水平相关(P<0.01)。
- 再分期时PSA 1.27 ng/mL为区分阳性与阴性PET/CT的最佳cutoff。
核心结论
- 18F-胆碱PET/CT有助于识别早期复发,即使PSA水平较低(<1 ng/mL)。
- 作者认为过去5年在18F-胆碱图像解读和患者选择方面已取得重要改进。
研究设计与样本
- 多中心回顾性队列研究,基于意大利9个核医学科收集的数据。
- 2008年10月至2019年9月间,3343例男性在接受原发性前列腺癌根治性治疗前或生化复发时接受18F-胆碱PET/CT。
- 纳入标准为组织学证实的前列腺癌(手术标本或未手术患者的前列腺活检)以及可获得包括PET/CT扫描时血清PSA水平在内的临床和病理资料。
主要发现
- 18F-胆碱PET/CT用于分期545例(16.4%),用于再分期2798例(83.6%);分期组阳性540例(99.1%),再分期组阳性1993例(71.2%)。
- 阳性PET/CT结果始终与高Gleason评分(>7)和高PSA水平相关(P<0.01)。
- 行PET/CT时PSA阈值低于1.0 ng/mL的患者比例在2014至2019年为25%(n=341),高于2008至2013年的16%(n=148)。
- 分期时,受试者工作特征分析显示区分局部病变阳性与阴性PET/CT的最佳PSA cutoff为9.2 ng/mL,淋巴结受累为16.4 ng/mL,转移为16.6 ng/mL。
- 再分期时,区分阳性与阴性PET/CT的最佳PSA cutoff为1.27 ng/mL。
关键数值与推荐
- 分期时局部病变的最佳PSA cutoff为9.2 ng/mL。
- 分期时淋巴结受累的最佳PSA cutoff为16.4 ng/mL。
- 分期时转移的最佳PSA cutoff为16.6 ng/mL。
- 再分期时区分阳性与阴性PET/CT的最佳PSA cutoff为1.27 ng/mL。
临床怎么用
- 18F-胆碱PET/CT可用于前列腺癌分期与再分期。
- 作者认为18F-胆碱PET/CT有助于识别早期复发,即使PSA水平较低(<1 ng/mL)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The primary aim of this multicenter retrospective analysis is to examine the role of F-choline PET/CT as a diagnostic tool for staging and restaging prostate cancer (PCa) in a large population in the light of 10 years of clinical experience. A secondary aim of the study is to produce data on the predictors of a positive F-choline PET/CT result in the setting of PCa primaries and biochemical recurrences. MATERIALS AND METHODS: This multicenter retrospective cohort study is based on data collected by 9 Italian nuclear medicine departments. Between October 2008 and September 2019, 3343 men underwent F-choline PET/CT scans before receiving definitive treatments for a primary PCa or biochemical recurrence. Inclusion criteria were (1) histologically proven PCa (on surgical specimens or prostate biopsies from patients not treated surgically) and (2) availability of clinical and pathological data, including serum prostate specific antigen (PSA) level at the time of PET/CT scanning. RESULTS: F-choline PET/CT was performed in 545 cases (16.4%) for cancer staging and in 2798 (83.6%) for restaging purposes, and the result was positive in 540 (99.1%) for the former and 1993 (71.2%) for the latter. A positive PET/CT result was always associated with a high Gleason score (>7) and high PSA levels (P < 0.01). The percentage of patients with a PSA threshold less than 1.0 ng/mL for performing PET/CT was higher in the years 2014 to 2019 (n = 341, 25% of cases) than during the previous period (n = 148, 16%; in 2008-2013). When used for staging purposes, receiver operating characteristic analysis showed that PSA levels of 9.2, 16.4, and 16.6 ng/mL were the optimal cutoffs for distinguishing between positive and negative PET/CT findings for local disease, lymph node involvement, and metastasis, respectively. In the restaging setting, a PSA level of 1.27 ng/mL was the optimal cutoff for distinguishing between a positive and negative PET/CT scan. CONCLUSIONS: F-choline PET/CT can help identify early recurrences, even in the case of low PSA levels (<1 ng/mL). Our data suggest that important improvements have been made in the interpretation of F-choline images and in patient selection in the last 5 years.
引用
- Zattoni F, Ravelli I, Rensi M, et al. 10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients. Clin Nucl Med. 2020. PMID: 32558711. doi:10.1097/RLU.0000000000003125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。